Lysinia Therapeutics
Developing a new treatment for Glutaric Aciduria-1, a rare genetic disease affecting children.
team
Four founders combining academic rigor with practical drug discovery experience.Click to view:
Edward A. Kesicki / Robert J. DeVita / Sander M Houten / Michael B Lazarus
CEO Founder Founder Founder
The Science
Our drug molecule blocks the pathway that leads to accumulation of toxic glutaric acid in cells.Click to enlarge:
